The efficacy of both ADCs was further enhanced by combination with the PD-L1 antibody, which led to complete tumor remission in 4/5 and 3/5 of the mice when combined with hu-αEGFR-172 and hu-αEGFR(ACVC)-172, respectively. Here, CD274 is linked to neoplasm.